N/A
N=90
Comparison of Serum C Type Natriuretic Peptide Levels Between Polycystic Ovary Syndrome Patients and Healthy Women
Polycystic Ovary Syndrome · c Type Natriuretic Peptide · Menstrual Irregularity · Hyperandrogenism
Bottom Line
View on ClinicalTrials.gov: NCT04006171 ↗Enrolled (actual)
90
Serious AEs
—
Results posted
Nov 2021
Primary outcome: Primary: Serum CNP Levels of PCOS and Healthy Participants — 110; 57 pg/ml — p=0.004
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- C type natriuretic peptide (Diagnostic_test)
- Age
- Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Near East University, Turkey
- Primary completion
- Sep 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum CNP Levels of PCOS and Healthy Participants |
110; 57 | 0.004 sig |
| PRIMARY Roc Curve of CNP |
0.706 | 0.004 sig |
| SECONDARY Comparison of FSH and LH of PCOS and Healthy Women |
4.7; 4.97; 4.23; 5.36 | 0.171 |
| SECONDARY Serum Estradiol Levels of PCOS and Healthy Women |
31; 36.5 | 0.306 |
| SECONDARY Serum Tiroid Stimulating Hormone of PCOS and Healthy Women |
1.61; 1.47 | 0.795 |
| SECONDARY Serum Prolactin Levels of PCOS and Healthy Women |
17.21; 16.80 | 0.852 |
| SECONDARY Serum Androstenedione Levels of PCOS and Healthy Women |
148.89; 84.66 | <0.001 sig |
| SECONDARY Serum Dehydroepiandrosterone Sulfate (DHEAS) Levels of PCOS and Healthy Women |
304.55; 299.95 | 0.277 |
| SECONDARY Serum Total Testosterone Levels of PCOS and Healthy Women |
1.38; 0.92 | 0.006 sig |
| SECONDARY Serum Free Testosterone Levels of PCOS and Healthy Women |
1.71; 1.12 | <0.001 sig |
| SECONDARY Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women |
30.4; 59.4 | 0.014 sig |
| SECONDARY Free Androgen Index of Participants |
4.39; 1.55 | <0.001 sig |
| SECONDARY Serum Glucose, Total Cholesterol and Triglycerides Levels of Participants |
164; 171; 78; 77; 88.5; 89 | 0.947 |
| SECONDARY High Density Lipoprotein and Low Density Lipoprotein Levels of Participants |
53.82; 62.15; 98.50; 92.92 | 0.114 |
| SECONDARY Serum Insulin Levels of Participants |
7.10; 7.10 | 0.713 |
| SECONDARY Homeostatic Model Assessment of Insulin Resistance of Participants |
1.50; 1.45 | 0.886 |
Summary
Recent studies have shown that C natriuretic peptide is produced from granulosa cells, increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells through natriuretic peptide receptors. It is suggested that produced cGMP maintains the transport of oocytes via the gap junctions and leads to a continuous increase in cyclic adenosine monophosphate (cAMP) levels in the oocyte. An important role of increased internal cAMP levels in the oocyte is shown to suppress meiotic progression.
Deoxyribonucleic acid studies in animals have shown that expression of the natriuretic peptide precursor increases during the periovulatory period and shows that this increase decreases rapidly after luteinizing hormone / human chorionic gonadotropin (hCG) stimulation.Human studies have shown that after ovulation induction, the CNP level in follicular fluid decreases following ovulatory dose of hCG.Polycystic ovary syndrome (PCOS) is the most common endocrine disease in the reproductive period, characterized by hyperandrogenism, oligo-anovulation, and polycystic ovarian morphology on ultrasonography, and in an animal study investigating the relationship between CNP and PCOS, serum CNP levels were increased in polycystic ovary syndrome.CNP serum level is thought to show differences between healthy women and women with polycystic ovary syndrome.
Eligibility Criteria
Inclusion Criteria
- PCOS defined according to Rotterdam criteria
- Healthy normal menstruating women
Exclusion Criteria
- Diabetes mellitus
- Cardiavascular disease
- Renal disease
- Any drug usage
- Smoking
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT04006171). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.